Article citationsMore>>
Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., Casey Jr., D.E., Colvin, M.M., Drazner, M.H., Filippatos, G.S., Fonarow, G.C., Givertz, M.M., Hollenberg, S.M., Lindenfeld, J., Masoudi, F.A., McBride, P.E., Peterson, P.N., Stevenson, L.W. and Westlake, C. (2017) 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Journal of Cardiac Failure, 23, 628-651.
https://doi.org/10.1016/j.cardfail.2017.04.014
has been cited by the following article:
-
TITLE:
Dapagliflozin and Spironolactone Improved Clinical Symptoms and CV Outcomes in Patient with HF Preserved Ejection Fraction (HFpEF) in Hard-to-Reach Rural African Population: A Case Series
AUTHORS:
Dominick Mkombozi Raphael, Abdu Hussein Mogella, Elias Edrick Mtalemwa, Beatrice Kabuka
KEYWORDS:
HFpEF, Spironolactone, Dapagliflozin, Africans Population
JOURNAL NAME:
Case Reports in Clinical Medicine,
Vol.11 No.11,
November
9,
2022
ABSTRACT: Objective: To observe the benefit of mineralocorticoid receptor antagonist and sodium-glucose co-transport 2 inhibitor (SGLT2 inhibitor) in heart failure preserved ejection (HFpEF) in rural Tanzania. Background and Result: The use of spironolactone and dapagliflozin was shown to be effective in improving the clinical outcome and reducing CV hospitalization rate and CV mortality in patients with heart failure preserved left ventricular ejection fraction (HFpEF). This is the case presentation of one patient with HFpEF with diastolic dysfunction grade 3, obesity grade 3, Type 2 Diabetes, and Atrial Fibrillation (permanent). In the case of a 76-year-old female after previous ineffective treatment, the initiation of Spironolactone and Dapagliflozin led to a rapid and marked improvement in the clinical conditions. Diastolic dysfunction was improved from stage III to stage I. Moreover, the initiation of spironolactone and dapagliflozin therapy avoided a referral for surgical intervention and interrupted a long series of hospitalizations for acute HF and prevented CV death. Conclusion: Based on our experience, we conclude that the treatment with spironolactone and dapagliflozin allows for better treatment optimization with a positive impact on the control of clinical outcomes and preventing CV death and CV hospitalization in HFpEF and related comorbidities in the African population, which is underrepresented in most of the trials.
Related Articles:
-
N. Moatassim Billah, L. Hammani, F. Z. Gueddari, A. Ajana, I. Nassar
-
Mohamed Sanhoury, Samar Elsayed, Abdallah Mostafa Almaghraby, Mahmoud Hassanein, Asmaa Alkafafy
-
E. Chauvelot, V. Nerich, S. Limat, M. F. Seronde, M. C. Woronoff-Lemsi
-
C. Pater, T. Severin
-
Bassirima Traoré, Souleymane Mariko, Samba Sidibé, Karamoko Kantako, Mariam Sako, Massama Konaté, Nouhoum Diallo, Abdoul Karim Sacko, Kalifa Diallo, Youssouf Kassambara, Djibril Kassogue, Oumar Ongoiba, Oumar Sanogo, Ichaka Menta, Souleymane Coulibaly